Minerva Neurosciences | NERV - Actif À Court Terme





Actif À Court Terme Changement Date
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
Adma Biologics USD 466.51M 63.86M 2025-12
ALKERMES USD 1.93B 187.5M 2025-12
Alterity Therapeutics Limited AUD 27.05M 6.16M 2023-06
AstraZeneca USD 28.72B 1.22B 2025-12
BioCryst Pharmaceuticals USD 404.35M 48.66M 2025-12
Bristol-Myers Squibb USD 35.63B 2.41B 2025-09
Cipla INR 249.18B 16.3B 2025-09
Clal Biotechnology ILS 14.69M 1.95M 2023-12
Compugen USD 148.02M 59.1M 2025-12
CSL USD 11.85B 1000K 2025-12
Eli Lilly USD 55.63B 6.44B 2025-12
Esperion Therapeutics USD 462.57M 102.11M 2025-12
GlaxoSmithKline GBP 17.51B 332M 2025-12
Grifols EUR 5.96B 316.31M 2025-12
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
Ionis Pharmaceuticals USD 2.99B 471.01M 2025-12
J&J USD 55.62B 1.01B 2025-12
Merck USD 47.56B 10.49B 2025-09
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Neurocrine Biosciences USD 2.52B 364.3M 2025-12
Novartis USD 30.46B 2.26B 2025-12
Novavax USD 978.28M 3.69M 2025-12
Pfizer USD 46.92B 3.22B 2025-09
Roche Holding CHF 38.73B 3.03B 2025-12
Sanofi EUR 30.95B 3.09B 2025-12
Takeda JPY 3.12T 195.82B 2025-12
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12